1
2
3
4
5
6
7
8
9
10
11
12
13 | Licensing Program Analyst (LPA) Melissa Parks arrived unannounced on Thursday March 7th, 2024, to complete and deliver findings to a complaint received on 1/9/2024. LPA met with Administrator Marc and explained the purpose of the visit.
Throughout the course of the investigation, LPA interviewed the Administrator, staff, and R1’s hospice team. LPA reviewed R1’s file at the facility including physicians report, MARs, medication count sheet, and medication list. The result of the investigation is as follows:
LPA reviewed R1’s medication list and verified that the medications were listed and being given according to the MAR. According to the medication count sheet, R1 was given one dose of PRN Lorazepam .5 mg on 12/3/2023, 12/4/2023, and 12/5/2023. According to the Clinical Director of R1’s hospice agency, this was the appropriate dosage based on R1’s symptoms. They stated that the life span of this drug is approximately six hours and therefore could not affected the resident for days after it was taken. The clinical director stated that the facility was appropriately given the medication. |